Compare
Nexgel, Inc. vs Medinotec Inc. vs Neuroone Medical Technologies Corp vs InspireMD, Inc.
| Latest fiscal year | Nexgel, Inc. NXGL | Medinotec Inc. MDNC | Neuroone Medical Technologies Corp NMTC | InspireMD, Inc. NSPR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-02-28 | 2025-09-30 | 2025-12-31 |
| Revenue | $11.42M | $9.73M | $9.10M | $8.98M |
| Revenue growth (YoY) | +31.5% | +6.8% | +163.5% | +28.1% |
| Gross margin | 39.5% | 52.7% | 56.5% | 29.5% |
| Operating margin | -29.3% | 11.2% | -46.5% | -552.6% |
| Net margin | -26.3% | 8.2% | -39.6% | -543.3% |
| Net income | -$3.00M | $794.5K | -$3.61M | -$48.79M |
| EPS (Diluted) | -$0.38 | n/a | -$0.09 | -$0.76 |
| Operating cash flow | -$1.31M | $906.8K | -$2.84M | -$35.10M |
| Free cash flow | -$1.38M | $905.4K | -$2.92M | -$36.77M |
| Cash & equivalents | n/a | n/a | $6.57M | $8.94M |
| Total assets | $10.46M | $6.81M | $10.79M | $69.40M |
| Total liabilities | $5.57M | $1.10M | $3.71M | $14.20M |
| Shareholders' equity | $4.46M | $5.71M | $7.07M | $55.20M |
| Return on year-end equity | -67.3% | 13.9% | -51.0% | -88.4% |
| Shares outstanding | 8.14M | 11.76M | 50.01M | 43.53M |
Revenue, most recent five fiscal years
| Fiscal year | Nexgel, Inc. | Medinotec Inc. | Neuroone Medical Technologies Corp | InspireMD, Inc. |
|---|---|---|---|---|
| Latest | $11.42M Ended 2025-12-31 | $9.73M Ended 2026-02-28 | $9.10M Ended 2025-09-30 | $8.98M Ended 2025-12-31 |
| 1 year earlier | $8.69M Ended 2024-12-31 | $9.11M Ended 2025-02-28 | $3.45M Ended 2024-09-30 | $7.01M Ended 2024-12-31 |
| 2 years earlier | $4.09M Ended 2023-12-31 | $5.02M Ended 2024-02-29 | $1.95M Ended 2023-09-30 | $6.21M Ended 2023-12-31 |
| 3 years earlier | $2.05M Ended 2022-12-31 | $999.6K Ended 2023-02-28 | $171.2K Ended 2022-09-30 | $5.17M Ended 2022-12-31 |
| 4 years earlier | $1.55M Ended 2021-12-31 | n/a | $178.1K Ended 2021-09-30 | $4.50M Ended 2021-12-31 |